JournalsHub
.online
Find My Journal
MM

Masahiro Morise

Nagoya University JP

ORCID iD 0000-0001-6576-3349
186
Publications
7,387
Citations
28
H-Index
59
i10-Index
6.04
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Publications

0 total

Favorable clinical impact of histological subtype with non-small cell carcinoma-not otherwise specified in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.

T. Hirano, Ichidai Tanaka, M. Morise, Junji Koyama, Takahiko Hashimoto - Respiratory Investigation, 2026
Cited by 0 Semantic Scholar

Clinical benefit of PD-1/PD-L1 inhibitors for poor performance status patients with advanced non-small cell lung cancer

Junji Koyama, M. Morise, I. Tanaka, Sho Hori, R. Matsuzawa - Journal of chemotherapy, 2025
Cited by 0 Semantic Scholar

Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study

S. Niho, Y. Goto, R. Toyozawa, H. Daga, K. Ohashi - ESMO Open, 2024
Cited by 8 Semantic Scholar

Rapidly progressive interstitial lung disease with positive anti-MDA5 antibody as an immune-related complication of nivolumab: A case report.

Sayaka Kato, Koji Sakamoto, Tomonori Sato, Tomoko Kobayashi, Yuichiro Shindo - Respiratory Investigation, 2024
Cited by 2 Semantic Scholar

Real-time ultrasound-guided thoracentesis simulation using an optical see-through head-mounted display: a proof-of-concept study OA

S. Okachi, T. Matsui, Manami Sakurai, T. Ito, M. Morise - Journal of Ultrasonography, 2024
Cited by 1 Semantic Scholar

Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial OA

R. Matsuzawa, M. Morise, K. Ito, O. Hataji, Kosuke Takahashi - EClinicalMedicine, 2023
Cited by 9 Semantic Scholar

INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. OA

Egbert F Smit, C. Dooms, J. Raskin, E. Nadal, L. Tho - Future Oncology, 2021
Cited by 53 Semantic Scholar

Research Topics

Lung Cancer Treatments and Mutations (97) Lung Cancer Research Studies (57) Lung Cancer Diagnosis and Treatment (50) Cancer Immunotherapy and Biomarkers (29) Gastric Cancer Management and Outcomes (18)

Affiliations

Tokai University
JP 2022 - 2020
Nagoya City University
JP 2021 - 2021
Nagoya University Hospital
JP 2023 - 2019
Kitasato University Hospital
JP 1998 - 1998
Respiratory Clinical Trials
AU 2024 - 2024

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now